These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9023291)

  • 1. LY303870, a centrally active neurokinin-1 antagonist with a long duration of action.
    Iyengar S; Hipskind PA; Gehlert DR; Schober D; Lobb KL; Nixon JA; Helton DR; Kallman MJ; Boucher S; Couture R; Li DL; Simmons RM
    J Pharmacol Exp Ther; 1997 Feb; 280(2):774-85. PubMed ID: 9023291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist.
    Gitter BD; Bruns RF; Howbert JJ; Waters DC; Threlkeld PG; Cox LM; Nixon JA; Lobb KL; Mason NR; Stengel PW
    J Pharmacol Exp Ther; 1995 Nov; 275(2):737-44. PubMed ID: 7473161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intrathecal injection of Sar9, Met(O2)11-substance P, neurokinin-1 receptor agonist, increases nitric oxide synthase expression and nitric oxide production in the rat spinal cord].
    Sun XC; Li WB; Li SQ; Li QJ; Chen XL; Ai J
    Sheng Li Xue Bao; 2003 Dec; 55(6):677-83. PubMed ID: 14695485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat.
    Cellier E; Barbot L; Iyengar S; Couture R
    Br J Pharmacol; 1999 Jun; 127(3):717-28. PubMed ID: 10401563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
    Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
    Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The nonpeptide NK-1 receptor antagonists LY303870 and LY306740 block the responses of spinal dorsal horn neurons to substance P and to peripheral noxious stimuli.
    Radhakrishnan V; Iyengar S; Henry JL
    Neuroscience; 1998 Apr; 83(4):1251-60. PubMed ID: 9502263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of tachykinin NK-1 and NK-3 receptor binding sites in the spinal cord of spontaneously hypertensive rat: impact on the autonomic control of blood pressure.
    Cloutier F; Ongali B; Deschamps K; Brouillette J; Neugebauer W; Couture R
    Br J Pharmacol; 2006 May; 148(1):25-38. PubMed ID: 16491095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice.
    Rupniak NM; Carlson EC; Harrison T; Oates B; Seward E; Owen S; de Felipe C; Hunt S; Wheeldon A
    Neuropharmacology; 2000 Jun; 39(8):1413-21. PubMed ID: 10818257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [3H]LY303870, a novel nonpeptide radioligand for the NK-1 receptor.
    Gehlert DR; Schober DA; Hipskind PA; Gitter BD; Howbert JJ
    J Neurochem; 1996 Mar; 66(3):1095-102. PubMed ID: 8769871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo pharmacological characterization of the novel NK₁ receptor selective antagonist Netupitant.
    Rizzi A; Campi B; Camarda V; Molinari S; Cantoreggi S; Regoli D; Pietra C; Calo' G
    Peptides; 2012 Sep; 37(1):86-97. PubMed ID: 22732666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
    Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
    J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists.
    Hipskind PA; Howbert JJ; Bruns RF; Cho SS; Crowell TA; Foreman MM; Gehlert DR; Iyengar S; Johnson KW; Krushinski JH; Li DL; Lobb KL; Mason NR; Muehl BS; Nixon JA; Phebus LA; Regoli D; Simmons RM; Threlkeld PG; Waters DC; Gitter BD
    J Med Chem; 1996 Feb; 39(3):736-48. PubMed ID: 8576917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrathecally-administered histamine facilitates nociception through tachykinin NK1 and histamine H1 receptors: a study in histidine decarboxylase gene knockout mice.
    Yoshida A; Mobarakeh JI; Sakurai E; Sakurada S; Orito T; Kuramasu A; Kato M; Yanai K
    Eur J Pharmacol; 2005 Oct; 522(1-3):55-62. PubMed ID: 16212954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist.
    Megens AA; Ashton D; Vermeire JC; Vermote PC; Hens KA; Hillen LC; Fransen JF; Mahieu M; Heylen L; Leysen JE; Jurzak MR; Janssens F
    J Pharmacol Exp Ther; 2002 Aug; 302(2):696-709. PubMed ID: 12130734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs.
    Phebus LA; Johnson KW; Stengel PW; Lobb KL; Nixon JA; Hipskind PA
    Life Sci; 1997; 60(18):1553-61. PubMed ID: 9126877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
    Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
    Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of Fos-like immunoreactivity in guinea-pig brain following administration of the neurokinin-1 receptor agonist, [SAR9,MET(O2)11]substance P.
    Yip J; Chahl LA
    Neuroscience; 1999; 94(2):663-73. PubMed ID: 10579226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo characterization of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonist.
    Kudlacz EM; Shatzer SA; Knippenberg RW; Logan DE; Poirot M; van Giersbergen PL; Burkholder TP
    J Pharmacol Exp Ther; 1996 May; 277(2):840-51. PubMed ID: 8627566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor.
    McLean S; Ganong A; Seymour PA; Bryce DK; Crawford RT; Morrone J; Reynolds LS; Schmidt AW; Zorn S; Watson J; Fossa A; DePasquale M; Rosen T; Nagahisa A; Tsuchiya M; Heym J
    J Pharmacol Exp Ther; 1996 May; 277(2):900-8. PubMed ID: 8627572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils.
    Nordquist RE; Durkin S; Jacquet A; Spooren W
    Eur J Pharmacol; 2008 Dec; 600(1-3):87-92. PubMed ID: 18930726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.